Why Pfizer’s Deal May Change the System of Taxing Multinationals
The United States approach has been a failure, and a $ 152 billion drug merger could nudge tax-writing committees in Washington into action.
Why Pfizer’s Deal May Change the System of Taxing Multinationals
The United States approach has been a failure, and a $ 152 billion drug merger could nudge tax-writing committees in Washington into action.
Ireland, Accused of Giving Tax Breaks to Multinationals, Plans an Even Lower Rate
The country will cut its 12.5 percent corporate tax rate in half for revenues pegged to patents and other intellectual property.